(MENAFN- GlobeNewsWire - Nasdaq) Bagsværd, Denmark, 11 November 2025 - This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	David Moore
2	Reason for the notification
a)	Position/status	Executive Vice President, US Operations
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Other transaction (acquisition of shares in accordance with the recruitment package)
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	DKK 0.00	18,634
d)	Aggregated information Aggregated volume Price	18,634 shares DKK 0.00
e)	Date of the transaction	2025-11-10
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name of the Board member/Executive/Associated Person	David Moore
2	Reason for the notification
a)	Position/status	Executive Vice President, US Operations
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)
a)	Description of the financial instrument, type of instrument,	Shares
	Identification code	Novo Nordisk B DK0062498333
b)	Nature of the transaction	Sale of shares
c)	Price(s) and volume(s)		Price(s)	Volume(s)
	DKK 297.95	8,160
d)	Aggregated information Aggregated volume Price	8,160 shares DKK 2,431,301.74
e)	Date of the transaction	2025-11-10
f)	Place of the transaction	Nasdaq Copenhagen

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:
Ambre James-Brown +45 3079 9289 ...	Liz Skrbkova (US) +1 609 917 0632 ...
Investors:
Jacob Martin Wiborg Rode +45 3075 5956 ...	Sina Meyer +45 3079 6656 ...
Christoffer Sho Togo Tullin +45 3079 1471 ...	Alex Bruce +45 34 44 26 13 ...
Frederik Taylor Pitter +1 609 613 0568 ...

Company announcement No 33 / 2025

Attachment

• CA251111-insider-trading

MENAFN11112025004107003653ID1110327055